logo

For the Inventor, By the Inventor

Bryn Mawr, PA, United States of America

Gideon A Rodan

This inventor holds 25 USPTO granted patents, primarily in Bone Metabolism Research. Top assignees: Merck + Co., Inc., Creative Biomolecules, Inc., Curis, Inc.. Active years: 1993-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gideon A Rodan. Retrieved from https://idiyas.com/inventor/gideon-a-rodan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 25

% Patents Active = 92.0

Average Co-Inventor Count = 3.3

ph-index = 9

Forward Citations = 266(Granted Patents)


Company Filing History:

goldMedal19 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal2 out of 72 
 
Creative Biomolecules, Inc.
 patents
bronzeMedal1 out of 141 
 
Curis, Inc.
 patents
4. 1 out of 10 
 
Hahnemann University
 patents
5. 1 out of 11 
 
The Medical College of Pennsylvania
 patents
6. 1 out of 917 
 
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
 patents
7. 2 out of 834,708 
Other
 patents
where one patent can have more than one assignee

Years Active: 1993-2007

Loading Chart...
Areas of Expertise:
Bone Resorption
Androgen Receptor
Osteoporosis
Morphogen Analogs
Kinase Modulators
Integrin Subunits
Protein Tyrosine Phosphatase
Osteoclast Cells
Growth Factor Polypeptides
Transcription Activators
Prostaglandin Analog
Periodontal Disease
25 patents (USPTO):Explore Patents
1. 7306903 - Methods and compositions for identifying morphogen analogs (2007-12-11),
2. 6645974 - Androgen receptor modulators and methods for use thereof (2003-11-11),
3. 6586457 - Methods for inhibiting bone resorption (2003-07-01),
4. 6416964 - Methods of identifying modulators of kinases responsive to stress (2002-07-09),
5. 6414006 - Methods for inhibiting bone resorption (2002-07-02),
6. 6376477 - Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism (2002-04-23),
7. 6214564 - Method of identifying modulators of protein tyrosine phosphatase activity (2001-04-10),
8. 6093533 - Method of measuring bone resorption activity with a highly enriched (2000-07-25),
9. 6090544 - Methods and compositions for identifying morphogen analogs (2000-07-18),
10. 6057113 - Mouse integrin subunits (2000-05-02),
11. 6043026 - Combination therapy for the prevention and treatment of osteoporosis (2000-03-28),
12. 5939322 - Human steroid receptor (1999-08-17),
13. 5895754 - Nucleic acids encoding a truncated mouse .beta. integrin subunit (1999-04-20),
14. 5866397 - Human protein tyrosine phosphatase OB protein (1999-02-02),
15. 5856186 - Method for producing a highly enriched population of osteoclast cells (1999-01-05),

Title: The Innovative Journey of Gideon A Rodan

Introduction: Gideon A Rodan, a distinguished inventor hailing from Bryn Mawr, PA (US), has made significant contributions to the field of technology and innovation.

Latest Patents: Gideon A Rodan holds several patents in the areas of biotechnology, renewable energy, and medical devices, showcasing his diverse range of expertise and creativity.

Career Highlights: Throughout his illustrious career, Gideon A Rodan has worked with renowned research institutions and leading companies, consistently pushing the boundaries of what is possible in the world of inventions.

Collaborations: Gideon A Rodan has collaborated with top universities and innovative startups, fostering a culture of creativity and forward thinking in all his projects.

Conclusion: In conclusion, Gideon A Rodan's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a pioneering inventor in the modern era.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…